Serological biomarkers in hemophilic arthropathy: Can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia?

E. Carlos Rodríguez-Merchán

doi:https://doi.org/10.1016/j.blre.2019.100642

doi.org/10.1016/j.blre.2019.100642

Serological biomarkers in hemophilic arthropathy: Can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia?

E. Carlos Rodríguez-Merchán

26

Blood Reviews7.40

Volume: 41, Pages: 100642 - 100642

Published: May 1, 2020

Abstract

In patients with hemophilia, levels of uCTX-II and sCS846 increase 5 days after joint hemorrhage with respect to the initial value. In other words, in patients with established hemophilic arthropathy, the aforesaid biomarkers of joint tissue damage augment shortly after the first joint hemorrhage. In patients with hemophilia treated on demand, a correlation has been found between magnetic resonance imaging scores and the CS846 biomarker....